In a report released on April 1, David Risinger from Leerink Partners maintained a Buy rating on AnaptysBio (ANAB – Research Report). The ...

Amtivo Group acquires International Standards Authority Inc. ISA brings expertise in ISO 9001 certification and has built a ...

AnaptysBio, Inc. (ANAB) shares rallied 30.5% in the last trading session to close at $16.15. This move can be attributable to notable volume with a higher number of shares being traded than in a ...

AnaptysBio, Inc. (ANAB) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2024. This widely-known consensus ...

AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that its Board of Directors has authorized a Stock ...

Has AnaptysBio, Inc. (ANAB) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.

ANAB remains risky despite new clinical data and partnerships; past successes haven't been replicated, and management's transparency issues raise concerns. The recent deal for Imsidolimab reflects ...

Explore AnaptysBio stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for ANAB. Intuitive Machines Posts Q4 Results, Joins Tesla, AnaptysBio, Coherent And Other ...